File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Treatment for lupus nephritis: A revisit

TitleTreatment for lupus nephritis: A revisit
Authors
KeywordsCyclophosphamide
Ethnic difference
Histological staging
Lupus nephritis
Mycophenolate mofetil
Prognosis
Issue Date2005
PublisherBlackwell Publishing Asia. The Journal's web site is located at http://www.blackwellpublishing.com/journals/NEP
Citation
Nephrology, 2005, v. 10 n. 2, p. 180-188 How to Cite?
AbstractThe optimal treatment of severe lupus nephritis remains unclear. Regimens consisting of steroid and cyclophosphamide (CYC) appear to be most effective. Infection and gonadal toxicity is a major concern of CYC use in patients of reproductive age. In addition, failure to respond or refractory to CYC treatment may lead to the development of end-stage renal disease. Mycophenolate mofetil (MMF) is a new immunosuppressive agent that selectively inhibits activated lymphocytes and renal mesangial cells. Data from experimental lupus nephritis and controlled studies, albeit small and lacking statistical power, have revealed that MMF is as effective in lupus patients as CYC in the induction of renal remission or as maintenance therapy to reduce renal flare in the short term. The significantly less ovarian toxicity and infection when compared to CYC are particularly attractive for the consideration of MMF in lupus nephritis. The potential of other new therapeutic agents is discussed together with the need for patient recruitment in future trials of lupus nephritis to address the importance of ethnicity as well as histological grading. © 2005 Asian Pacific Society of Nephrology.
Persistent Identifierhttp://hdl.handle.net/10722/77849
ISSN
2015 Impact Factor: 1.796
2015 SCImago Journal Rankings: 0.894
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorLai, KNen_HK
dc.contributor.authorTang, SCWen_HK
dc.contributor.authorMok, CCen_HK
dc.date.accessioned2010-09-06T07:36:25Z-
dc.date.available2010-09-06T07:36:25Z-
dc.date.issued2005en_HK
dc.identifier.citationNephrology, 2005, v. 10 n. 2, p. 180-188en_HK
dc.identifier.issn1320-5358en_HK
dc.identifier.urihttp://hdl.handle.net/10722/77849-
dc.description.abstractThe optimal treatment of severe lupus nephritis remains unclear. Regimens consisting of steroid and cyclophosphamide (CYC) appear to be most effective. Infection and gonadal toxicity is a major concern of CYC use in patients of reproductive age. In addition, failure to respond or refractory to CYC treatment may lead to the development of end-stage renal disease. Mycophenolate mofetil (MMF) is a new immunosuppressive agent that selectively inhibits activated lymphocytes and renal mesangial cells. Data from experimental lupus nephritis and controlled studies, albeit small and lacking statistical power, have revealed that MMF is as effective in lupus patients as CYC in the induction of renal remission or as maintenance therapy to reduce renal flare in the short term. The significantly less ovarian toxicity and infection when compared to CYC are particularly attractive for the consideration of MMF in lupus nephritis. The potential of other new therapeutic agents is discussed together with the need for patient recruitment in future trials of lupus nephritis to address the importance of ethnicity as well as histological grading. © 2005 Asian Pacific Society of Nephrology.en_HK
dc.languageengen_HK
dc.publisherBlackwell Publishing Asia. The Journal's web site is located at http://www.blackwellpublishing.com/journals/NEPen_HK
dc.relation.ispartofNephrologyen_HK
dc.subjectCyclophosphamideen_HK
dc.subjectEthnic differenceen_HK
dc.subjectHistological stagingen_HK
dc.subjectLupus nephritisen_HK
dc.subjectMycophenolate mofetilen_HK
dc.subjectPrognosisen_HK
dc.subject.meshHumansen_HK
dc.subject.meshImmunosuppressive Agents - therapeutic useen_HK
dc.subject.meshLupus Nephritis - drug therapyen_HK
dc.titleTreatment for lupus nephritis: A revisiten_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=1320-5358&volume=10&spage=180&epage=188&date=2005&atitle=Treatment+for+lupus+nephritis:+a+revisiten_HK
dc.identifier.emailLai, KN: knlai@hku.hken_HK
dc.identifier.emailTang, SCW: scwtang@hku.hken_HK
dc.identifier.authorityLai, KN=rp00324en_HK
dc.identifier.authorityTang, SCW=rp00480en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1111/j.1440-1797.2005.00372.xen_HK
dc.identifier.pmid15877679-
dc.identifier.scopuseid_2-s2.0-20144384491en_HK
dc.identifier.hkuros100100en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-20144384491&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume10en_HK
dc.identifier.issue2en_HK
dc.identifier.spage180en_HK
dc.identifier.epage188en_HK
dc.identifier.isiWOS:000228866700016-
dc.publisher.placeAustraliaen_HK
dc.identifier.scopusauthoridLai, KN=7402135706en_HK
dc.identifier.scopusauthoridTang, SCW=7403437082en_HK
dc.identifier.scopusauthoridMok, CC=34668219600en_HK
dc.identifier.citeulike180499-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats